Cited by 78Neuroendocrine Tumor Research AdvancesPancreatic function and diabetesPeptidase Inhibition and Analysis

Innovative imaging of insulinoma: the end of sampling? A review

Open access
Christ, Emanuel, Antwi, Kwadwo, Fani, Melpomeni, Wild, Damian·2020·Endocrine-Related Cancer

Abstract

Receptors for the incretin glucagon-like peptide-1 (GLP-1R) have been found overexpressed in selected types of human tumors and may, therefore, play an increasingly important role in endocrine gastrointestinal tumor management. In particular, virtually all benign insulinomas express GLP-1R in high density. Targeting GLP-1R with indium-111, technetium-99m or gallium-68-labeled exendin-4 offers a new approach that permits the successful localization of small benign insulinomas. It is likely that this new non-invasive technique has the potential to replace the invasive localization of insulinomas by selective arterial stimulation and venous sampling. In contrast to benign insulinomas, malignant insulin-secreting neuroendocrine tumors express GLP-1R in only one-third of the cases, while they more often express the somatostatin subtype 2 receptors. Importantly, one of the two receptors appears to be always overexpressed. In special cases of endogenous hyperinsulinemic hypoglycemia (EHH), that is, in the context of MEN-1 or adult nesidioblastosis GLP-1R imaging is useful whereas in postprandial hypoglycemia in the context of bariatric surgery, GLP-1R imaging is probably not helpful. This review focuses on the potential use of GLP-1R imaging in the differential diagnosis of EHH.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1530/erc-19-0476

Cites

94 of 94 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • SACS was the gold standard in the past to detect an insulin gradient in the vessels supplying the pancreas, and this invasive method might be almost completely replaced by PET imaging in the future, e.g., with 68Ga DOTA-Exendin-4 PET/CT.

    “While SACS was the gold standard in the past to detect an insulin gradient in the vessels supplying the pancreas, this invasive method might be almost completely replaced by PET imaging in the future, e.g., with 68 Ga DOTA-Exendin-4 PET/CT [38-41].”

    From An Uncommon Cause of Recurrent Presyncope, Dizziness, and Tachycardia: A Case Report of Diffuse, Adult-Onset Nesidioblastosis/Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) (2023) · cites this paper as [40]

    The Introduction (page unavailable) describes SACST as an invasive test recommended when conventional imaging cannot localize an insulinoma; it samples hepatic venous blood for insulin to identify an arterial territory. The Conclusion (page unavailable) predicts that GLP-1R imaging could end the need for SACST. The review does not call SACST a past gold standard, and its recommendation is limited to cases not localized by conventional imaging. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Wild D Béhé M Wicki A Storch D Waser B Gotthardt M Keil B Christofori G Reubi JC Mäcke HR 2006 Lys40(Ahx-DTPA-111In)NH2. Journal of Nuclear Medicine 2025– 2033. 17138746

Cited by

Sorted by citations

Authors
Christ, E., Antwi, K., Fani, M., & Wild, D.
Affiliations
  • University of Basel (CH)
  • University Hospital of Basel (CH)
Corresponding author
Christ, Emanuel
Venue
Endocrine-Related Cancer
Published
2020-04
Volume
27
Issue
4
Pages
R79-R92
ISSN
  • 1351-0088 (ISSN-L)
  • 1479-6821
OpenAlex
W3000462399
Cited by
78
References
94
Citations by year
2026: 3 · 2025: 15 · 2024: 11 · 2023: 18 · 2022: 15 · 2021: 9 · 2020: 6 · 2019: 1
FWCI
1.75
Type
journal article
Language
en
Open access
Locations
  • Endocrine Related Cancer (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Science Foundation
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (38912, 152938, 320030)
Topics
  • Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
  • Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
  • Health Sciences › Medicine › Oncology › Peptidase Inhibition and Analysis
Keywords
insulinoma, exendin-4, gallium-68, indium-111, technetium-99m, neuroendocrine tumors, somatostatin receptor 2, endogenous hyperinsulinemic hypoglycemia, multiple endocrine neoplasia type 1, nesidioblastosis, bariatric surgery, tumor localization, differential diagnosis
MeSH terms
Positron Emission Tomography Computed Tomography, Diagnostic Imaging, Female, Humans, Insulinoma, Male, Prospective Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review